Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Partnership - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen outside of mainland China [1] - This collaboration aims to develop multiple tissue regeneration products for the medical aesthetics sector, leveraging the low immunogenicity and virus-free characteristics of Giant Bio's recombinant collagen [1] Group 2: Market Potential - The injection-based medical aesthetics market is projected to reach a market size of $10 billion by 2026, highlighting significant growth opportunities for the partnership [2] - The collaboration is expected to enhance Nordberg Medical's innovation capabilities in regenerative medicine by providing a richer product line [2] Group 3: Industry Impact - The partnership is seen as a milestone for both companies, with Giant Bio's technology being recognized as a "Chinese technology business card" in the international market [2] - The collaboration is anticipated to have a profound impact on the global medical aesthetics industry, promoting high-quality health solutions for consumers and practitioners [2]
巨子生物携手瑞典Nordberg Medical，迈向“生态出海”新阶段